Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating Pneumococcal Conjugate Vaccine

The company’s investigational 15-valent pneumococcal conjugate vaccine met its primary immunogenicity objectives.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: